May 28, 2015
Raze Therapeutics Announces Addition of Robert Copeland, PhD, to Scientific Advisory Board

April 8, 2015
In new Nature paper, Raze Therapeutics co-founder David Sabatini discovers role for 1C metabolism in glioblastoma

April 7, 2015
Raze Therapeutics Appoints Mark Manfredi as Chief Scientific Officer

January 7, 2015
Raze Therapeutics Announces Addition of Julian Adams, PhD,
George Q. Daley, MD, PhD, and Karen Vousden, PhD, to Scientific Advisory Board

November 18, 2014
In new paper, Raze Therapeutics co-founder Josh Rabinowitz and colleagues discover 1C metabolism generates oncometabolite known to drive tumors

October 28, 2014
Raze Therapeutics Appoints Mikel Moyer, PhD, as Vice President, Molecular Discovery

December 1, 2014
In new paper, Raze Therapeutics co-founder Josh Rabinowitz and colleagues discover role for 1C metabolism in neuroblastoma and oxygen-starved tumors

October 14, 2014
Raze Therapeutics Launches with $24 Million Series A Financing to Advance a New Class of Oncology Therapeutics Targeting Metabolic Pathways Essential to Cancer Growth and Survival